Trevena CEO to Present at the 2011 BIO CEO and Investor Conference
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc., the industry leader in discovery and development of biased GPCR ligands, announced today that Maxine Gowen, Ph.D., president and chief executive officer of Trevena, will make a presentation at the 13th annual BIO CEO and Investor Conference in New York next week. Dr Gowen will address the conference at 8:00am on Tuesday February 15th.
Trevena, Inc. is a clinical stage pharmaceutical company focused on discovering and developing the next generation of G-protein coupled receptor (GPCR) targeted medicines. Trevena designs "biased ligands" that activate only those biological pathways at the receptor associated with beneficial effects, allowing them to unlock new biology and avoid drug side effects.
TRV120027 is the most advanced drug in Trevena's pipeline, and the first biased ligand to be tested in humans. Trevena is working to develop TRV120027 for the treatment of acute decompensated heart failure. Phase 1 clinical studies of the drug were successfully completed last year, and planning for Phase 2 studies is underway. Trevena's pipeline also includes earlier stage programs with potential in pain and inflammation. Founded in 2008, Trevena is based in King of Prussia, Pennsylvania and is a privately held company backed by leading investors including Alta Partners, Healthcare Ventures, NEA, Polaris and Yasuda Enterprise Development Company. For more information about the company, please visit www.trevenainc.com.
Source: Trevena, Inc.
Released February 11, 2011